The Supreme Court only hears patent cases approximately 7% of the time. Therefore, the Supreme Court's rejection of the case was largely anticipated and the Appellate court decision remains in place. Merck has exhausted all avenues to regain U.S. exclusivity beyond February 2008, at which point generics are expected. -John Boris

 

The Supreme Court only hears patent cases approximately 7% of the time. Therefore, the Supreme Court's rejection of the case was largely anticipated and the Appellate court decision remains in place. Merck has exhausted all avenues to regain U.S. exclusivity beyond February 2008, at which point generics are expected.


Comments

There are not yet any comments on this quote. Why not register / login and be the first?



This quote is just one of 6 total John Boris quotes in our collection. John Boris is known for saying 'The Supreme Court only hears patent cases approximately 7% of the time. Therefore, the Supreme Court's rejection of the case was largely anticipated and the Appellate court decision remains in place. Merck has exhausted all avenues to regain U.S. exclusivity beyond February 2008, at which point generics are expected.' as well as some of the following quotes.

Anything that hints of a weaker top line doesn't play too well with the Street. We believe there's a tad bit of disconnect, and the modest contraction in the stock has created a good buying opportunity.

John Boris
183

We expect the price spread to increase from 28% to more than 70% with additional generic launches.

John Boris
115
We believe the downside risk from current levels is limited anchored by Merck offering an attractive 4.4% dividend. -John Boris
92

There could be a much higher rate of suicide with people not taking their medications, than with people taking their medication.

John Boris
88

The faster Merck appoints [Clark] as chairman, the better the signal is.

John Boris
54
The Supreme Court only hears patent cases approximately 7% of the time. Therefore, the Supreme Court's rejection of the case was largely anticipated and the Appellate court decision remains in place. Merck has exhausted all avenues to regain U.S. exclusivity beyond February 2008, at which point generics are expected. -John Boris
47